The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Japan's Nikkei Stock 225 closed up by +1.97%. December 10-year T-notes (ZNZ24) Thursday closed down by -16.5 ticks.  The 10-year T-note yield rose +6.3 bp to 3.844%. Dec T-notes Thursday tumbled to a ...

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...

The UK’s publicly funded healthcare system has proposed phasing its rollout of Eli Lilly’s weight loss treatment tirzepatide ...

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...

The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making ...

LEBANON, Ind. (WFFT) — Eli Lilly and Company announced another $4.5 billion investment in Lebanon’s LEAP Research and ...